GlycoNex (ROCO:4168) Total Liabilities : NT$322.87 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Total Liabilities?

GlycoNex's Total Liabilities for the quarter that ended in Mar. 2024 was NT$322.87 Mil.

GlycoNex's quarterly Total Liabilities increased from Sep. 2023 (NT$261.02 Mil) to Dec. 2023 (NT$276.40 Mil) and increased from Dec. 2023 (NT$276.40 Mil) to Mar. 2024 (NT$322.87 Mil).

GlycoNex's annual Total Liabilities increased from Dec. 2021 (NT$36.07 Mil) to Dec. 2022 (NT$271.34 Mil) and increased from Dec. 2022 (NT$271.34 Mil) to Dec. 2023 (NT$276.40 Mil).

GlycoNex Total Liabilities Historical Data

The historical data trend for GlycoNex's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex Total Liabilities Chart

GlycoNex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

31.36

34.47

36.07

271.34

276.40

GlycoNex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															258.46	265.38	261.02	276.40	322.87

GlycoNex Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

GlycoNex's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	270.583	+	(0	+	5.816
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	276.40

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1552.814	-	1276.415
	=	276.40

GlycoNex's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	317.082	+	(0	+	5.784
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	322.87

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1525.393	-	1202.527
	=	322.87

GlycoNex Total Liabilities Related Terms

Thank you for viewing the detailed overview of GlycoNex's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoNex (ROCO:4168) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221

Website

http://www.glyconex.com.tw

GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.

GlycoNex (ROCO:4168) Headlines

No Headlines